Skip to Main Content
Try STAT+ TODAY
Trending:
Biotech
Pharmalot
Coronavirus
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

What’s going on at Grail?

  • Damian Garde

By Damian Garde Oct. 30, 2017

Reprints
UCSF Cancer Center - DNA samples
Justin Sullivan/Getty Images

There are plenty of reasons to envy Grail, the Google-backed company seeking to revolutionize how cancer is diagnosed. The company has raised more than $1 billion, pulled off a series of high-profile hires, and made a splash in the New England Journal of Medicine.

But organizational stability may not be one of them.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

Who will get the call from Stockholm? It’s time…
Who will get the call from Stockholm? It’s time for STAT’s 2022 Nobel Prize predictions
‘Microdosing’ is touted by ’shroomers and Reddit users. Science…
‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims —…
CAR-T therapy doesn’t work in all cancer cases. Scientists…
CAR-T therapy doesn’t work in all cancer cases. Scientists are starting to figure out why
At Verily, a growing line of business builds on…
At Verily, a growing line of business builds on a revolving door to the FDA
Pharmalittle: Price of new ALS drug prompts criticism; many…
Pharmalittle: Price of new ALS drug prompts criticism; many drug price hikes exceeded U.S. inflation rate
Many trials to confirm benefits of drugs granted accelerated…
Many trials to confirm benefits of drugs granted accelerated approvals are running late

Recommended Stories